SiriusXM Satellite Radio (SIRI): Shares of SiriusXM Satellite Radio closed higher on Friday by five percent, right at the buck-eighty mark, barely two weeks after a market downturn and some negative press pushed the stock to a low of $1.27 on high volume.
Since then, SiriusXM has further pushed into the used car market by announcing a deal with Nissan (OTCPK:NSANY), who will offer a three month subscription on used car purchases, and hype surrounding the upcoming launch of the Sirius 2.0 platform is building steam as well.
The retreat to $1.50 and below was quick but short-lived, and shares might be trucking higher to two dollars again.
Human Genome Sciences (HGSI): Human Genome Sciences spent much of last week dipping down into ten dollar territory, following a temporary move higher that materialized after a positive sales update from the company. The dropping HGSI shares could be attributed to a general market downswing that took place since the sales update, but the decision by UK medical authorities to not recommend coverage of Benlysta for lupus, partnered with GlaxoSmithKline (GSK), also added some uncertainty into the mix. Some investors are skeptical as well that Benlysta sales will never approach even the revamped sales expectations.
It also doesn't hurt that Jim Cramer slapped a strong sell on this stock during an airing last week.
Key for this company will be a third quarter earnings report that supports the positive sales growth that was said to exceed expectations in a late-September announcement. Should investors get the impression that the sales numbers are on track, then confidence could be restored in this otherwise - as Cramer put it - "speculative" investment.
Concerning the decision by the UK medical authorities, that is something that will probably be overturned after negotiations among HGSI, partner GSK and the British regulators. It's no secret that governments are broke these days, with much of that situation being attributed to high health care costs, and the regulators are standing firm on their mission to push companies to lower the cost of their drugs and treatments.
Look for updates on the situation in the UK, the last word most likely has not yet been uttered.
Google (GOOG): Even the behemoth Google made waves last week, when more than double the normal volume sent shares higher by six percent on Friday after an earnings announcement that surpassed expectations.
Google's strong earnings, sparked by solid Google Mobile revenue and earnings of $1.50 a share higher than the same quarter last year, and strong numbers for the Apple (AAPL) iPhone 4S launch, sent shares around the technology sector higher.
It looks as if the last bastion of doubters is shifting course regarding their opinions that Google could infiltrate the mobile market with huge success, as the company proved during the past quarter that its Android technology and foothold in mobile search are here to stay.
Just another step forward for this technology giant, that looks to get its hands into every aspect of the global economy.
Keryx Biopharmaceuticals (KERX): Shares of Keryx Biopharmaceuticals took a seven percent haircut on Friday, but hit even lower during intra day trading after double-the-norm volume and comments made by a Doctor on a popular biotech blog sent skittish investors running as shares started to slip.
Before the comments hit the wires on Friday, indicating that the Phase III trial for the cancer agent Perifisone would fail in late stage trials, KERX had been a stock trying to rebound from recent lows.
Keryx is also scheduled to announce results for Zerenex, an oral compound intended to treat hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, next year.
With results from late stage trials for both of KERX's pipeline due next year, this stock has been a candidate of a pre-trial run, and still might be since Friday's modest haircut was wholly unconvincing, and the negative opinion by the Doctor was worthy only of a 'mailbag' appearance on the popular blog, and not of a story of its own.
Keryx is also an acquisition candidate, and volatility is sure to play a key role in the stock's future leading into trial results.
For those still confident in this company's future, Friday's dip opened up a pretty good buying opportunity.
One to watch.
Capstone Turbine (CPST): Now hovering between a buck and a buck-ten after briefly dipping to below ninety cents, Capstone Turbine (CPST) looks to be consolidating in a familiar area as investors again weigh the company's future prospects for profitability.
Ampio Pharmaceuticals (AMPE): Another company whose shares slipped as a result of the market downturn and heavy short interest, Ampio Pharmaceuticals rebounded over the past week to over eight dollars. The company also announced last week that trial information for its lead product candidate, Ampio, would be presented at San Fransisco's American Association of Orthopedic Surgery (AAOS) meeting in February 2012.
Spectrum Pharmaceuticals (SPPI): Spectrum Pharmaceuticals has continued to rebound from recent lows as revenue has increased and the company's long term potential has been solidified by recent developments. The coming months should also bring a decision from the FDA regarding the possible removal of the bioscan requirement for Zevalin treatment, another milestone that could positively impact the future of Spectrum's revenue stream. Possibly another Jazz Pharmaceuticals (JAZZ) in the making.
Celsius Holdings (OTCPK:CELH): Volume picked up a bit for Celsius Holdings last week, which isn't saying too much since volume has been slim for months, but with another earnings report due, some interest might be heading the way of this company looking to rebound from a year-long stock price plunge.
Could be worth keeping this one on the radar again, as the past two quarters demonstrated sales stability of its calorie-burning drink and lower company costs. Another quarter of stability could be what Celsius needs to attract some renewed investor attention.
Geron (GERN): Geron's modes rebound held up last week, with shares closing at $2.34 on Friday. The leader of the embryonic stem cell generation has been hammered this year, but ongoing trials and its progress in stem cell research makes this a perennial stock to watch. The recent dip has opened up a nice buying opp for those looking to play the embryonic research field, with due notice also to the dip in Advanced Cell Technology (OTCQB:ACTC).